Cardiovascular Risk Assessment for Primary Care

News
Slideshow

Cardiovascular risk assessment is mostly science but also an art, in part. Get an at-a-glance review here of the risk factors and algorithms that combine both.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension / image credit ©Sundry Photos

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension

Grace Halsey
September 16th 2025
Article
Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Sydney Jennings
September 16th 2025
Podcast
High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults / Image credit: University of Copenhagen

High-Dose Influenza Vaccine Reduces Risk of Myocarditis and Pericarditis in Older Adults

Sydney Jennings
September 16th 2025
Article
The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
September 16th 2025
Podcast
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial

Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial

Patient Care Editorial Staff
September 16th 2025
Article
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

Sydney Jennings
September 16th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.